CenTrial Logo

Can Direct Oral Anticoagulants be Used in Stroke Prevention?


Clinical trial shows that direct oral anticoagulants are more effective in preventing stroke

A recent clinical trial has shown that a new class of drugs called direct oral anticoagulants (DOACs) is better than the old drug warfarin in preventing stroke in patients with atrial fibrillation.

Atrial fibrillation is a condition that causes the heart to beat irregularly, increasing the risk of blood clots forming in the heart, which can then travel to the brain, causing a stroke.
A stroke, sometimes called a brain attack, occurs when something blocks the blood supply to part of the brain or when a blood vessel in the brain bursts. The affected part of the brain becomes damaged or dies. A stroke can cause long-term damage or disability and can even result in death.

Direct Oral Anticoagulants (DOACs) are a relatively new class of drugs used to prevent blood clots in patients with Atrial Fibrillation. Warfarin has been used for many years however; DOACs are now more popular due to fewer side effects.

A recent clinical study compared DOACs to warfarin in patients with atrial fibrillation. The clinical study combined data from multiple previous clinical trials to create a larger sample size for analysis. The study included over 71,000 patients from 20 clinical trials.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
The clinical study found that only 3.01% of the patients receiving DOACs experienced a stroke compared to 3.69% of patients receiving warfarin. This indicates that there was a 19% lower risk of stroke in patients receiving DOACs. There was also a lower risk of bleeding and death. This is a significant advantage as the major side effect of warfarin is bleeding.

The clinical study also found that DOACs were equally effective in both men and women and patients of all ages.

Overall, the clinical trial provides strong evidence that DOACs are a safe and effective alternative to warfarin in patients with atrial fibrillation. The findings of this clinical study are also very important for doctors as they now have an additional drug to prevent stroke in patients with atrial fibrillation. However, patients need to consult their doctors before starting either drug therapy.

In conclusion, the clinical study provides important insights into the use of DOACs compared to warfarin in patients with atrial fibrillation. The results suggest that DOACs are more effective at preventing strokes and have a lower risk of major bleeding events than warfarin. The study also found that DOACs are equally effective in both men and women and patients of all ages.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Whether you're healthy or have a medical condition you can participate in a clinical trial.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.